Mechanism of the inhibitory effect of melatonin on tumor necrosis factor production in vivo and in vitro

European Journal of Pharmacology

Volumn 343, Issue 2-3, 1998, Pages 249-255

  Sacco, Silvano ^a   Aquilini, Luciano ^b   Ghezzi, Pietro ^a   Pinza, Mario ^b   Guglielmotti, Angelo ^b  

^a Laboratory of Neuroimmunology   (Italy)

^b Università Politecnica delle Marche ACRAF Gruppo Angelini   (Italy)

Author keywords

Antioxidant; Endotoxin; Melatonin; TNF (tumor necrosis factor )

Indexed keywords

5 METHOXYTRYPTAMINE; ANTIOXIDANT; CORTICOSTERONE; INDOLEAMINE; LIPOPOLYSACCHARIDE; MELATONIN; N ACETYLSEROTONIN; RECOMBINANT INTERLEUKIN 1BETA; SEROTONIN; TUMOR NECROSIS FACTOR ALPHA;

ADRENALECTOMY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIOXIDANT ACTIVITY; ARTICLE; BRAIN; CONTROLLED STUDY; CORTICOSTERONE BLOOD LEVEL; DRUG MECHANISM; HUMAN; HUMAN CELL; HYPOPHYSECTOMY; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; LETHALITY; MALE; MONONUCLEAR CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; SEPTIC SHOCK; SUBCUTANEOUS DRUG ADMINISTRATION; SURVIVAL;

ADRENAL GLANDS; ANIMALS; ANTIOXIDANTS; CORTICOSTERONE; HYPOTHALAMO-HYPOPHYSEAL SYSTEM; INTERLEUKIN-2; LEUKOCYTES, MONONUCLEAR; LIPOPOLYSACCHARIDES; MALE; MELATONIN; MICE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0032545961     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(97)01545-8     Document Type: Article

References (38)

1. Artz E., Costas M., Finkielman S., Nahmod E. Serotonin inhibition of TNF-α synthesis by human monocytes. Life Sci. 48:1991;2557-2562.
2. Ben-Nathan D., Maestroni G.J., Lustig S., Conti A. Protective effects of melatonin in mice infected with encephalitis viruses. Arch. Virol. 140:1995;223-230.
3. Benigni F., Villa P., Demitri M.T., Sacco S., Sipe J.D., Lagunowich L., Panayotatos N., Ghezzi P. Ciliary neurotrophic factor (CNTF) inhibits brain and peripheral TNF production and, in association with its soluble receptor, protects mice against LPS toxicity. Mol. Med. 1:1995;568-575.
4. Beutler B., Milsark I.W., Cerami A.C. Passive immunization against cachectin/TNF protects mice from lethal effect of endotoxin. Science. 229:1985;869-871.
5. Brzezinski A. Melatonin in humans. N. Engl. J. Med. 336:1997;186-195.
6. Chaudri G., Clark I.A. Reactive oxygen species facilitate the in vitro and in vivo lipopolysaccharide-induced release of TNF. J. Immunol. 143:1989;1290-1294.
7. Chuang J.I., Mohan N., Meltz M.L., Reiter R.J. Effect of melatonin on NF-κB DNA-binding activity in the rat spleen. Cell. Biol. Int. 20:1996;687-692.
8. De Boer M., Reijneke R., Van de Griend R.J., Loos J.A., Roos D. Large-scale purification and cryopreservation of human monocytes. J. Immunol. Methods. 43:1981;225-239.
9. Di Stefano A., Paulesu L. Inhibitory effect of melatonin on production of IFNγ or TNFα in peripheral blood mononuclear cells of soime blood donors. J. Pineal Res. 17:1994;164-169.
10. Dinarello C.A. Biologic basis for interleukin-1 in disease. Blood. 87:1996;2095-2147.
11. Dubocovich M.L. Melatonin receptors: Are there multiple subtypes? Trends Pharmacol. Sci. 16:1995;50-56.
12. Eugui E.M., DeLustro B., Rouhafza S., Ilnicka M., Lee S.W., Wilhelm R., Allison A.C. Some antioxidants inhibit, in a co-ordinate fashion, the production of TNF-alpha, IL-beta and IL-6 by human peripheral blood mononuclear cells. Int. Immunol. 6:1994;409-422.
13. Evans G.F., Snyder Y.M., Butler L.D., Zuckerman S.H. Differential expression of interleukin-1 and TNF in murine septic shock models. Circ. Shock. 29:1989;279-290.
14. Faggioni R., Fantuzzi G., Villa P., Buurman W., van Tits L.J.H., Ghezzi P. Independent down-regulation of central versus peripheral TNF by LPS tolerance. Infect. Immun. 63:1995;1473-1477.
15. Falconi G., Rossi G.L. Transauricular hypophysectomy in rats and mice. Endocrinology. 74:1964;301-305.
16. Fantuzzi G., Ghezzi P. Glucocorticoids as cytokine inhibitors: Role in neuroendocrine control and therapy of inflammatory diseases. Mediat. Inflamm. 2:1993;263-270.
17. Fantuzzi G., Di Santo E., Sacco S., Benigni F., Ghezzi P. Role of the hypothalamus-pituitary-adrenal axis in the regulation of TNF production in mice: Effect of stress and inhibition of endogenous glucocorticoids. J. Immunol. 155:1995;3552-3555.
18. Gadina M., Bertini R., Mengozzi M., Zandalisini M., Mantovani A., Ghezzi P. Protective effect of chlorpromazine on endotoxin toxicity and TNF production in glucocorticoid-sensitive and glucocorticoid-resistant models of endotoxic shock. J. Exp. Med. 173:1991;1305-1310.
19. Gwinner E., Benzinger I. Synchronization of a circadian rhythm in pinealectomized European starlings by daily injections of melatonin. J. Comp. Physiol. 127:1978;209-213.
20. Haley T.J., McCormick W.G. Pharmacological effects produced by intracerebral injection of drugs in the conscious mice. Br. J. Pharmacol. 12:1957;12-15.
21. Halliwell B., Gutteridge J.M.C., Aruoma O.I. The deoxyribose method: A simple 'test-tube' assay for determination of rate constants for reaction of hydroxyl radicals. Anal. Biochem. 165:1987;215-219.
22. Le Bars D., Thivolle P., Vitte P.A., Bojkowski C., Chazot G., Arendt J., Frackowiak R.S., Claustrat B. PET and plasma pharmacokinetics studies after bolus intravenous administration of [11C]-melatonin in humans. Nucl. Med. Biol. 18:1991;357-362.
23. Lesniewska B., Nowak M., Nussdorfer G., Malendowicz L. Sex-dependent effect of melatonin on the secretory activity of rat and hamster adrenal gland in vitro. Life Sci. 47:1990;241-245.
24. Lipton J.M., Macaluso A., Hiltz M.E., Catania A. Central administration of the peptide α-MSH inhibits inflammation in the skin. Peptides. 12:1991;795-798.
25. Maestroni G.J. Melatonin as a therapeutic agent in experimental endotoxic shock. J. Pineal Res. 20:1996;84-89.
26. Manev H., Cagnoli C.M., Kharlamov A., Atabay C., Kharlamov E. In vitro and in vivo neuroprotection with melatonin against the toxicity of singlet oxygens. Soc. Neurosci. Abstr. 21:1995;1518.
27. Melchiorri D., Sewerynek E., Reiter R.J., Ortiz G.G., Poeggeler B., Nistico G. Suppressive effect of melatonin administration on ethanol-induced gastroduodenal injury in rats in vivo. Br. J. Pharmacol. 121:1997;264-270.
28. Melchiorri M., Reiter R.J., Attia A.M., Hara M., Burgos A., Nisticò G. Potent protective effect of melatonin on in vivo paraquat-induced oxidative damage in rats. Life Sci. 56:1995;83-89.
29. Peristeris P., Clark B.D., Gatti S., Faggioni R., Mantovani A., Mengozzi M., Orencole S.F., Sironi M., Ghezzi P. N-acetylcysteine and glutathione as inhibitors of TNF production. Cell. Immunol. 140:1992;390-399.
30. Pieri C., Marra M., Gaspar R., Damjanovich S. Melatonin protects LDL from oxidation but does not prevent the apolipoprotein derivatization. Biochem. Biophys. Res. Commun. 222:1996;256-260.
31. Popova J., Dubocovich M.L. Melatonin receptor-mediated stimulation of phosphoinositide breakdown in chick brain slices. J. Neurochem. 64:1995;130-138.
32. Reiter R.J., Tang L., Garcia J.J., Munoz-Hoyos A. Pharmacological actions of melatonin in oxygen radical pathophysiology. Life Sci. 60:1997;2255-2271.
33. Schreck R., Meier B., Mannel D., Dröge W., Baeuerle P.A. Dithiocarbamates as potent inhibitors of NF-κB activation in intact cells. J. Exp. Med. 175:1992;1181-1194.
34. Sewerynek E., Melchiorri D., Reiter R.J., Ortiz G.G., Lewinski A. Lipopolysaccharide-induced hepatotoxicity is inhibited by the antioxidant melatonin. Eur. J. Pharmacol. 293:1995;327-334.
35. Tan D.Z., Chen L.D., Poeggeler B., Manchester L.C., Reiter R.J. Melatonin: A potent, endogenous hydroxyl radical scavenger. Endocr. J. 1:1993;57-60.
36. Tracey K.J., Cerami A. Tumor necrosis factor, other cytokines and disease. Annu. Rev. Cell. Biol. 9:1993;317-343.
37. Yamada K. Effects of melatonin on adrenal function in male rats. Res. Commun. Chem. Pathol. Pharmacol. 69:1990;241-244.
38. Zhang H., Spapen H., Nguyen D.N., Benlabed M., Buurman W.A., Vincent J.L. Protective effect of N-acetyl-L-cysteine in endotoxemia. Am. J. Physiol. 266:1994;H1746-H1754.